Top

Journal of Experimental & Clinical Cancer Research

Published in:

01-12-2020 | Metastasis | Research

Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis

Authors: Wenkang Luan, Yuting Ding, Haitao Yuan, Shaojun Ma, Hongru Ruan, Jinlong Wang, Feng Lu, Xuefeng Bu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Abstract

Background

Long intergenic non-protein coding RNA 520 (LINC00520), a novel identified lncRNA, has been shown to modulate the malignant phenotype of tumor cells in some malignant tumors. However, the exact role and molecular mechanism of LINC00520 in malignant melanoma has not been studied.

Methods

The expression of LINC00520 in melanoma tissues were detected by using RNA-seq analysis and qRT-PCR. Melanoma cases from the public databases (The Cancer Genome Atlas (TCGA), GEO#GSE15605, GEO#GSE34460 and GEO#GSE24996) were included in this study. CCK-8 assay, EdU assay, transwell and scratch wound assay were used to explore the role of LINC00520 in melanoma cells. Luciferase reporter assays, MS2-RIP, RNA pull-down and RNA-ChIP assay were used to demonstrate the molecular biological mechanism of LINC00520 in melanoma.

Results

We found that LICN00520 was found to be overexpressed in melanoma tissue. High expression of LICN00520 is a risk factor for the prognosis of melanoma patients. LINC00520 promotes the proliferation, invasion and migration of melanoma cells. LICN00520 exerted its oncogenic role by competitive binding miR-125b-5p to promote Eukaryotic initiation factor 5A2 (EIF5A2) expression. We also showed that LICN00520 promotes the growth and metastasis of melanoma in vivo through regulating miR-125b-5p/EIF5A2 axis.

Conclusions

All results elucidated the role and molecular mechanism of LINC00520 in the malignant development of melanoma. LINC00520, a new oncogene in melanoma, maybe serve as a survival biomarkers or therapeutic target for melanoma patients.

Available only for authorised users

Haass NK, Schumacher U. Melanoma never says die. Exp Dermatol. 2014;23(7):471–2. https://doi.org/10.1111/exd.12400.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, et al. YB-1 expression and phosphorylation regulate Tumorigenicity and invasiveness in melanoma by influencing EMT. Mol Cancer Res. 2018;16(7):1149–60. https://doi.org/10.1158/1541-7786.MCR-17-0528.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131–55. https://doi.org/10.1101/gad.191999.112.CrossRefPubMedPubMedCentral

Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863(4):770–84.CrossRefPubMed

Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14. https://doi.org/10.1016/j.molcel.2011.08.018.CrossRefPubMedPubMedCentral

Schmitt AM, Chang HY. Long noncoding RNAs in Cancer pathways. Cancer Cell. 2016;29(4):452–63. https://doi.org/10.1016/j.ccell.2016.03.010.CrossRefPubMedPubMedCentral

Lingadahalli S, Jadhao S, Sung YY, Chen M, Hu L, Chen X, et al. Novel lncRNA LINC00844 regulates prostate Cancer cell migration and invasion through AR signaling. Molecular cancer research : MCR. 2018;16(12):1865–78. https://doi.org/10.1158/1541-7786.MCR-18-0087.CrossRefPubMed

10.

Luan W, Ding Y, Ma S, Ruan H, Wang J, Lu F. Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis. Cell Death Dis. 2019;10(11):855.CrossRefPubMedPubMedCentral

11.

Luan W, Zhang X, Ruan H, Wang J, Bu X. Long noncoding RNA OIP5-AS1 acts AS a competing endogenous RNA to promote glutamine catabolism and malignant melanoma growth by sponging miR-217. J Cell Physiol. 2019. https://doi.org/10.1002/jcp.28335.CrossRef

12.

Henry WS, Hendrickson DG, Beca F, Glass B, Lindahl-Allen M, He L, et al. LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer. Oncotarget. 2016;7(50):81981–94.CrossRefPubMedPubMedCentral

13.

Wu YY, Gao W, Zhang YL, Niu M, Cui JJ, Xiang CX, et al. Expression and clinical significance of long non-coding RNA LINC00520 in laryngeal squamous cell carcinoma. Lin chuang er bi yan hou tou jing wai ke za zhi. 2018;32(2):91–5. https://doi.org/10.13201/j.issn.1001-1781.2018.18.019.CrossRefPubMed

14.

Xie T, Pi G, Yang B, Ren H, Yu J, Ren Q, et al. Long non-coding RNA 520 is a negative prognostic biomarker and exhibits pro-oncogenic function in nasopharyngeal carcinoma carcinogenesis through regulation of miR-26b-3p/USP39 axis. Gene. 2019;707:44–52. https://doi.org/10.1016/j.gene.2019.02.093.CrossRefPubMed

15.

Mei XL, Zhong S. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR. Chin Med J. 2019;132(4):454–65. https://doi.org/10.1097/CM9.0000000000000070.CrossRefPubMedPubMedCentral

16.

Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52. https://doi.org/10.1038/nature12986.CrossRefPubMedPubMedCentral

17.

Luan W, Li L, Shi Y, Bu X, Xia Y, Wang J, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016;7(39):63901–12. https://doi.org/10.18632/oncotarget.11564.CrossRefPubMedPubMedCentral

18.

Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001;71(1):101–9. https://doi.org/10.1006/geno.2000.6418.CrossRefPubMed

19.

Bao Y, Lu Y, Wang X, Feng W, Sun X, Guo H, et al. Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition. Cancer Cell Int. 2015;15:109.CrossRefPubMedPubMedCentral

20.

Liu RR, Lv YS, Tang YX, Wang YF, Chen XL, Zheng XX, et al. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species. Oncotarget. 2016;7(17):24348–60. https://doi.org/10.18632/oncotarget.8324.CrossRefPubMedPubMedCentral

21.

Sun J, Xu Z, Lv H, Wang Y, Wang L, Ni Y, et al. eIF5A2 regulates the resistance of gastric cancer cells to cisplatin via induction of EMT. Am J Transl Res. 2018;10(12):4269–79.PubMedPubMedCentral

22.

Li Y, Fu L, Li JB, Qin Y, Zeng TT, Zhou J, et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology. 2014;146(7):1701–13 e9. https://doi.org/10.1053/j.gastro.2014.02.029.CrossRefPubMed

23.

Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer. 2014;110(2):399–408. https://doi.org/10.1038/bjc.2013.688.CrossRefPubMed

24.

Ni X, Ding Y, Yuan H, Shao J, Yan Y, Guo R, et al. Long non-coding RNA ZEB1-AS1 promotes colon adenocarcinoma malignant progression via miR-455-3p/PAK2 axis. Cell Proliferat. 2020;53(1):e12723.

25.

Liu H, Dai C, Wu Q, Liu H, Li F. Expression profiling of long noncoding RNA identifies lnc-MMP3-1 as a prognostic biomarker in external auditory canal squamous cell carcinoma. Cancer medicine. 2017;6(11):2541–51. https://doi.org/10.1002/cam4.1213.CrossRefPubMedPubMedCentral

26.

Subramanian M, Li XL, Hara T, Lal A. A biochemical approach to identify direct microRNA targets. Methods Mol Biol. 2015;1206:29–37.CrossRefPubMedPubMedCentral

27.

Luan W, Wang Y, Chen X, Shi Y, Wang J, Zhang J, et al. PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget. 2015;6(15):13006–18. https://doi.org/10.18632/oncotarget.3514.CrossRefPubMedPubMedCentral

28.

Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, et al. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene. 2017;36(8):1157–66. https://doi.org/10.1038/onc.2016.286.CrossRefPubMed

29.

Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2014;33(18):2307–16. https://doi.org/10.1038/onc.2013.187.CrossRefPubMed

30.

Li Y, Wang L, Rivera-Serrano EE, Chen X, Lemon SM. TNRC6 proteins modulate hepatitis C virus replication by spatially regulating the binding of miR-122/Ago2 complexes to viral RNA. Nucleic Acids Res. 2019;47(12):6411–24. https://doi.org/10.1093/nar/gkz278.CrossRefPubMedPubMedCentral

31.

Luan W, Li R, Liu L, Ni X, Shi Y, Xia Y, et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p. Oncotarget. 2017;8(49):85401–14. https://doi.org/10.18632/oncotarget.19910.CrossRefPubMedPubMedCentral

32.

Davalos V, Esteller M. Disruption of Long noncoding RNAs targets Cancer Hallmark pathways in lung tumorigenesis. Cancer Res. 2019;79(12):3028–30. https://doi.org/10.1158/0008-5472.CAN-19-0910.CrossRefPubMed

33.

Chen B, Wang C, Zhang J, Zhou Y, Hu W, Guo T. New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma. Cancer Cell Int. 2018;18:157.CrossRefPubMedPubMedCentral

34.

Wang Y, Yang C, Liu X, Zheng J, Zhang F, Wang D, et al. Transcription factor AP-4 (TFAP4)-upstream ORF coding 66 aa inhibits the malignant behaviors of glioma cells by suppressing the TFAP4/long noncoding RNA 00520/microRNA-520f-3p feedback loop. Cancer Sci. 2020;111(3):891–906.CrossRefPubMedPubMedCentral

35.

Liu L, Shi Y, Shi J, Wang H, Sheng Y, Jiang Q, et al. The long non-coding RNA SNHG1 promotes glioma progression by competitively binding to miR-194 to regulate PHLDA1 expression. Cell Death Dis. 2019;10(6):463.CrossRefPubMedPubMedCentral

36.

Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Experiment Clin Cancer Res. 2018;37(1):289.CrossRef

37.

Sang M, Meng L, Liu S, Ding P, Chang S, Ju Y, et al. Circular RNA ciRS-7 maintains metastatic phenotypes as a ceRNA of miR-1299 to target MMPs. Mol Cancer Res. 2018;16(11):1665–75. https://doi.org/10.1158/1541-7786.MCR-18-0284.CrossRefPubMed

38.

Liu S, Chen Q, Wang Y. MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway. Hum Cell. 2020;33(1):185–94. https://doi.org/10.1007/s13577-019-00285-x.CrossRefPubMed

39.

Hua S, Quan Y, Zhan M, Liao H, Li Y, Lu L. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1. Cancer Cell Int. 2019;19:203.CrossRefPubMedPubMedCentral

40.

Yan J, Jiang Q, Lu H, Na S, Long S, Xin Y, et al. Association between microRNA-125b expression in formalin-fixed paraffin-embedded tumor tissues and prognosis in patients with melanoma. Oncol Lett. 2019;18(2):1856–62. https://doi.org/10.3892/ol.2019.10506.CrossRefPubMedPubMedCentral

41.

Zhang J, Lu L, Xiong Y, Qin W, Zhang Y, Qian Y, et al. MLK3 promotes melanoma proliferation and invasion and is a target of microRNA-125b. Clin Exp Dermatol. 2014;39(3):376–84. https://doi.org/10.1111/ced.12286.CrossRefPubMed

42.

Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7(4):4428–41. https://doi.org/10.18632/oncotarget.6599.CrossRefPubMed

43.

Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast cancer research : BCR. 2016;18(1):84.CrossRefPubMedPubMedCentral

44.

Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004;64(12):4197–200. https://doi.org/10.1158/0008-5472.CAN-03-3747.CrossRefPubMed

45.

Meng QB, Kang WM, Yu JC, Liu YQ, Ma ZQ, Zhou L, et al. Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer. PLoS One. 2015;10(3):e0119229. https://doi.org/10.1371/journal.pone.0119229.CrossRefPubMedPubMedCentral

46.

Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Invest. 2018;128(12):5505–16. https://doi.org/10.1172/JCI98060.CrossRefPubMedPubMedCentral

Title: Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis
Authors: Wenkang Luan
Yuting Ding
Haitao Yuan
Shaojun Ma
Hongru Ruan
Jinlong Wang
Feng Lu
Xuefeng Bu
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Metastasis
Melanoma
Melanoma
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-020-01599-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling

Cancer at the time of the COVID-19 hurricane

Transcription activation of circ-STAT3 induced by Gli2 promotes the progression of hepatoblastoma via acting as a sponge for miR-29a/b/c-3p to upregulate STAT3/Gli2

Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy

Reorganization of Istituti Fisioterapici Ospitalieri, an oncological and dermatological clinical and research center, to face the coronavirus health emergency: adopted measures and metrics of success to achieve and keep a COVID-19-free status

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Keynote webinar | Spotlight on antibody–drug conjugates in cancer